<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00571922</url>
  </required_header>
  <id_info>
    <org_study_id>06-632</org_study_id>
    <nct_id>NCT00571922</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction</brief_title>
  <acronym>AcampMet</acronym>
  <official_title>A Placebo-controlled, Double Blind, Randomized Trial of Acamprosate for the Treatment of Methamphetamine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will compare 10 week treatment with acamprosate (2 gr/day) versus
      placebo, combined with weekly abstinence oriented individual counseling, in methamphetamine
      dependent patients, 72 subjects will be enrolled, with an interim analysis scheduled after 36
      enrolled. Primary outcome is methamphetamine absitience over the 10 week treatment period,
      and the last 2 weeks of treatment. Abstinence is defined on a weekly basis as no urine
      positive of methamphetamine (or amphetamine) and self-report of not use for the 7 day period.
      Secondary measures include treatment retention, drug craving, mood, and safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methamphetamine Abstinence</measure>
    <time_frame>7 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Craving</measure>
    <time_frame>7 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Methamphetamine Dependence, Treatment Seeking</condition>
  <arm_group>
    <arm_group_label>Acamprosate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acamprosate</intervention_name>
    <description>2 gr/day (333 mg, TID)</description>
    <arm_group_label>Acamprosate</arm_group_label>
    <other_name>Campral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Methamphetamine dependence

          -  Treatment seeking

          -  Urine sample (+) for methamphetamine

        Exclusion Criteria:

          -  Pregnancy

          -  Dependence on other drugs (except nicotine)

          -  DSM-IV axis I disorder unrelated to drug abuse

          -  Serious medical condition in clinicians opinion.

          -  AIDs

          -  Untreated syphilis

          -  Allergy to acamprosate

          -  Methadone, or other ORP, maintenance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Reid, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA New York Harbor Healthcare System, MHAD clinic</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2007</study_first_submitted>
  <study_first_submitted_qc>December 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <results_first_submitted>February 5, 2016</results_first_submitted>
  <results_first_submitted_qc>March 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 6, 2016</results_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>methamphetamine, crystal, treatment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
    <mesh_term>Acamprosate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acamprosate</title>
          <description>Acamprosate: 2 gr/day (333 mg, TID)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo: matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Completion unknown</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acamprosate</title>
          <description>Acamprosate: 2 gr/day (333 mg, TID)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo: matching placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>PI passed away, and there is no access to data. Although the total number of subjects enrolled is known, information regarding baseline characteristics is unavailable.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">PI passed away, and there is no access to data. Although the total number of subjects enrolled is known, information regarding baseline characteristics is unavailable.</measurement>
                    <measurement group_id="B2" value="NA">PI passed away, and there is no access to data. Although the total number of subjects enrolled is known, information regarding baseline characteristics is unavailable.</measurement>
                    <measurement group_id="B3" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">PI passed away, and there is no access to data. Although the total number of subjects enrolled is known, information regarding baseline characteristics is unavailable.</measurement>
                    <measurement group_id="B2" value="NA">PI passed away, and there is no access to data. Although the total number of subjects enrolled is known, information regarding baseline characteristics is unavailable.</measurement>
                    <measurement group_id="B3" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">PI passed away, and there is no access to data. Although the total number of subjects enrolled is known, information regarding baseline characteristics is unavailable.</measurement>
                    <measurement group_id="B2" value="NA">PI passed away, and there is no access to data. Although the total number of subjects enrolled is known, information regarding baseline characteristics is unavailable.</measurement>
                    <measurement group_id="B3" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>PI passed away, and there is no access to data. Although the total number of subjects enrolled is known, information regarding baseline characteristics is unavailable.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">PI passed away, and there is no access to data. Although the total number of subjects enrolled is known, information regarding baseline characteristics is unavailable.</measurement>
                    <measurement group_id="B2" value="NA">PI passed away, and there is no access to data. Although the total number of subjects enrolled is known, information regarding baseline characteristics is unavailable.</measurement>
                    <measurement group_id="B3" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">PI passed away, and there is no access to data. Although the total number of subjects enrolled is known, information regarding baseline characteristics is unavailable.</measurement>
                    <measurement group_id="B2" value="NA">PI passed away, and there is no access to data. Although the total number of subjects enrolled is known, information regarding baseline characteristics is unavailable.</measurement>
                    <measurement group_id="B3" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Methamphetamine Abstinence</title>
        <time_frame>7 day</time_frame>
        <population>PI passed away, data is unavailable.</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>Acamprosate: 2 gr/day (333 mg, TID)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Methamphetamine Abstinence</title>
          <population>PI passed away, data is unavailable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Craving</title>
        <time_frame>7 day</time_frame>
        <population>PI passed away, data is unavailable</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>Acamprosate: 2 gr/day (333 mg, TID)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Craving</title>
          <population>PI passed away, data is unavailable</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>PI passed away, and there is no access to data. Information regarding adverse and serious adverse events is unavailable.</desc>
      <group_list>
        <group group_id="E1">
          <title>Acamprosate</title>
          <description>Acamprosate: 2 gr/day (333 mg, TID)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo: matching placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sadly, the PI of this study passed away on 4/20/2010. Data was not analyzed and is unavailable.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>The Office of Clinical Trials</name_or_title>
      <organization>NYU Langone Medical Center</organization>
      <phone>212.263.4210</phone>
      <email>clinicaltrials@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

